Patients & Providers How SelfWrap Works Company News Clinical Trial

Bioengineered Vascular Support

Designed to improve vascular surgery outcomes, starting with renal dialysis access

Learn About Our Clinical Trial

SelfWrap

A New Approach to Dialysis Access

SelfWrap is a bioabsorbable, flexible vascular wrap designed to reduce dialysis access site failures

Learn How it Works

Better Outcomes Are Needed

Dialysis is the primary lifeline for patients with end-stage renal disease, but dialysis access sites are prone to failure, reducing the quality and length of life for patients.

1 in 8

People worldwide suffer from chronic kidney disease ^{[1]Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:3-15. doi: 10.1007/978-981-13-8871-2_1.}

480K+

End-stage renal disease patients on hemodialysis in the US ^{[2]United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. End Stage Renal Disease, Chapter 3: Vascular Access. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.}

50-60%

Failure rate of dialysis access sites in the first year ^{[3]United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Chapter 3: Vascular Access. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.} ^{[4]Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, Kosa SD, Quinn RR, Moist LM. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014 Mar;63(3):464-78. doi: 10.1053/j.ajkd.2013.08.023. Epub 2013 Oct 30.}

$4B+

Annual Medicare costs due to access site failures ^{[5]Thamer M, Lee TC, Wasse H, Glickman MH, Qian J, Gottlieb D, Toner S, Pflederer TA. Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients. Am J Kidney Dis. 2018 Jul;72(1):10-18. doi: 10.1053/j.ajkd.2018.01.034. Epub 2018 Mar 28.}

Our Company

A Team of Experts Pioneering Novel Tissue Engineering Technology

Our cross-disciplinary team, with expertise in biomedical engineering, materials engineering and medical 3D printing, is applying this unique technology to improve the lives of vascular surgery patients.

About Venostent

News & Press

Bioengineered Vascular Support

Designed to improve vascular surgery outcomes, starting with renal dialysis access

A New Approach to Dialysis Access

A Team of Experts Pioneering Novel Tissue Engineering Technology

VenoStent Enrolls First Subjects in 200-Subject US Clinical Trial

VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US Trial

VenoStent Technology Receives Breakthrough Device Designation by FDA